Please upgrade your browser.
Sunitinib is approved for treatment of advanced renal cell carcinoma (rcc). Based on a clinical observation that patients receiving sunitinib developed macrocytosis, we undertook a study to further define this observation.
Joe Sheetz passed away in August 2006 at the age of 60 after a lengthy battle with kidney cancer. He was executive vice president of store development for 25 years. He was succeed by his son, Joe S. Sheetz.
If ridaforolimus is brought to market it would likely compete with Novartis oral mTOR inhibitor Afinitor, which was approved by the FDA last April.
A new study indicates that patients aged 75 years or older who have confined kidney tumors do not live longer if they have their entire kidney removed. The research reveals that these patients typically have other medical problems of greater significance and that many should receive more conservative cancer-related care, such as observation or treatments that spare the noncancerous parts of their kidneys.
Kidney cancer is not a single disease but comprises a number of different types of cancer that occur in the kidney, each caused by a different gene with a different histology and clinical course that responds differently to therapy.
There were only a few options 3 years ago to treat metastatic renal cell carcinoma (mRCC), a disease with a very poor prognosis. With the approval of targeted therapies for mRCC since December 2005, this situation has changed dramatically.
The association between renal cell carcinoma (RCC) risk and family history of cancer has not been examined with an adequate number of African Americans (AAs).
For example, women diagnosed with a rarer cancer like kidney cancer have only a 43% chance of living for five years in comparison to a 79% chance for breast cancer patients.
Previously reported studies suggested a connection between milk intake and renal cell carcinoma risk . . .
To investigate efficacy of neoadjuvant tyrosine kinase-inhibitor therapy (TKI) before imperative nephron-sparing surgery (NSS), as NSS in patients with large locally advanced or centrally located tumours can be challenging, and TKI therapy might result in a reduction of primary tumour burden and increase the feasibility of NSS.
|NeonCRM by Neon One|